The Role of m6A Ribonucleic Acid Modification in the Occurrence of Atherosclerosis

Abstract

The N6-methyladenosine (m6A) modification is the most abundant epitranscriptomic modification in eukaryotic messenger RNA (mRNA). The m6A modification process is jointly regulated by various enzymes and proteins, such as methyltransferases, demethylases and related m6A-binding proteins. The process is dynamic and reversible, and it plays an essential role in mRNA metabolism and various biological activities. Recently, an increasing number of researchers have confirmed that the onset and development of many diseases are closely associated with the molecular biological mechanism of m6A RNA methylation. This study focuses on the relationship between m6A RNA modification and atherosclerosis (AS). It thoroughly summarizes the mechanisms and processes of m6A RNA modification in AS-related cells and the relationships between m6A RNA modification and AS risk factors, and it provides a reference for exploring new targets for the early diagnosis and treatment of AS.

m6A ‘writer’ KIAA1429 regulates the proliferation and migration of endothelial cells in atherosclerosis

“…Increasing evidence synergistically indicates the potential vital roles of m 6 A modification on AS [ 22 ]. For instance, ox-LDL remarkably stimulation promotes the m 6 A modification level of macrophages in AS and METTL3 knockdown inhibits the oxLDL-induced inflammatory response and m 6 A modification [ 23 ].…”

N6-methyladenosine writer KIAA1429 modulates the proliferation/migration of endothelial cells for atherosclerosis

“…Increasing evidence synergistically indicates the potential vital roles of m 6 A modi cation on AS (Fu, et al, 2021). For instance, ox-LDL remarkably stimulation promotes the m 6 A modi cation level of macrophages in AS and METTL3 knockdown inhibits the oxLDL-induced in ammatory response and m 6 A modi cation (Li, et al, 2022c).…”

Potential Impact of N6-Methyladenosine RNA Methylation on Vision Function and the Pathological Processes of Ocular Diseases: New Discoveries and Future Perspectives

“…Notably, reduced m6A is suggested as a possible biomarker of type 2 diabetes [291]. ZFAS1 expression regulated by METTl14 has been shown to be significantly increased in patients with atherosclerosis compared with those without atherosclerosis, suggesting that m6A modification factors may be a novel biomarker for monitoring atherosclerosis susceptibility [292][293][294]. Moreover, the prognostic value of m6A methylation has also been reported in patients with uveal melanoma [290], bladder cancer [295], and colon cancer [296].…”